DBV Technologies S.A. American Depositary Shares

DBVT

Börsenwert 569 Mio. $

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population.  DBV has requested Priority Review of the BLA.

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format:         Fireside Chat Time:            1:00pm ETLocation:       New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format:         1 on 1 MeetingsLocation:       New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format:         Fireside ChatTime:            3:00pm ETLocation:      New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

Information Regarding the Total Number of Voting Rights and  Total Number of Shares of the Company as of August 31, 2026

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $50 million, before deducting sales agent commissions and offering expenses payable by the Company, to RA Capital Management, L.P (“RA Capital”) through Citizens JMP Securities, LLC (“Citizens”), acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.

DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60% of diagnosed children with adequate insurance coverage ultimately initiate treatment, reflecting Viaskin's favorable safety profile, user-friendly administration, and the significant burden of avoidance-only management. An initial backlog of untreated children creates a temporary annual revenue peak above $1.6bn before revenues stabilize around $1bn as the market reaches steady state.

DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in 2027.

Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company's previously established at-the-market offering program (the “ATM Program”) by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares (“ADS”). The ATM Program was established pursuant to a sales agreement dated September 5, 2025, (the “Sales Agreement”) with Citizens JMP Securities, LLC (“Citizens”), acting as sales agent, under which the Company may offer and sell, from time to time, ADSs, each ADS representing five ordinary shares of the Company, having an aggregate offering price of up to $150 million, subject to French regulatory limits.

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, while also building commercial infrastructure ahead of a potential U.S. launch.